首页IMC • ASX
add
Immuron Ltd
市场资讯
财务信息
损益表
收入
净收入
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | 127.36万 | 108.61% |
经营支出 | 255.89万 | 79.40% |
净收入 | -243.19万 | -169.00% |
净利润率 | -190.94 | -28.94% |
每股收益 | — | — |
息税折旧摊销前利润 | -167.92万 | -118.52% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1165.73万 | -32.07% |
总资产 | 1555.00万 | -29.28% |
负债总额 | 284.05万 | 19.79% |
权益总额 | 1270.94万 | — |
发行在外的股份 | 2.28亿 | — |
市净率 | 1.28 | — |
资产回报率 | -27.02% | — |
资本回报率 | -32.61% | — |
现金流
现金净变动
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | -243.19万 | -169.00% |
来自运营的现金 | -193.82万 | -141.79% |
投资现金 | 8.70万 | 1,082.80% |
融资现金 | 1.20万 | 203.57% |
现金净变动 | -177.81万 | -170.36% |
自由现金流 | -102.70万 | -197.20% |
简介
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
成立时间
1994
员工数量
7
